Skip to main content
SpringerLink
Log in

Beyond Weight Loss: Evaluating Cardiovascular Advantages of GLP-1 Receptor Agonists

  • Commentary
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

The Original Article was published on 11 May 2024

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. World Health Organization Obesity and Overweight. (accessed on 17 Apr 2024); Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

  2. Brandfon S, Eylon A, Khanna D, Parmar MS. Advances in anti-obesity pharmacotherapy: current treatments, emerging therapies, and challenges. Cureus. 2023;15(10): e46623. https://doi.org/10.7759/cureus.46623.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98. https://doi.org/10.1038/s41574-019-0176-8.

    Article  PubMed  Google Scholar 

  4. Blüher M, Aras M, Aronne LJ, Batterham RL, Giorgino F, Ji L, Pietiläinen KH, Schnell O, Tonchevska E, Wilding JPH. New insights into the treatment of obesity. Diabetes Obes Metab. 2023;25(8):2058–72. https://doi.org/10.1111/dom.15077.

    Article  CAS  PubMed  Google Scholar 

  5. Mariam Z, Niazi SK. Glucagon-like peptide agonists: a prospective review. Endocrinol Diabetes Metab. 2024;7(1): e462. https://doi.org/10.1002/edm2.462.

    Article  CAS  PubMed  Google Scholar 

  6. de Oliveira Almeida G, Nienkötter TF, Almeida Balieiro CC, et al. Cardiovascular benefits of GLP-1 receptor agonists in patients living with obesity or overweight: a meta-analysis of randomized controlled trials. J Am Cardiovasc Drugs. 2024. https://doi.org/10.1007/s40256-024-00647-3.

    Article  Google Scholar 

  7. El Meouchy P, Wahoud M, Allam S, Chedid R, Karam W, Karam S. Hypertension related to obesity: pathogenesis, characteristics and factors for control. Int J Mol Sci. 2022;23(20):12305. https://doi.org/10.3390/ijms232012305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, Chen Z, Luo S, Zheng X, Weng J, Xu S. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17(8):2050–68. https://doi.org/10.7150/ijbs.59965.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. https://doi.org/10.1056/NEJMoa2307563.

    Article  CAS  PubMed  Google Scholar 

  10. Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists onglycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384: e076410. https://doi.org/10.1136/bmj-2023-076410.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Brian Normanly (University of Valencia/CIBERehd; Brian.Normanly@uv.es) for his editorial assistance.

Author information

Authors and Affiliations

  1. Servicio de Digestivo, Hospital Universitario Virgen de las Nieves, 18014, Granada, Spain

    Teresa Vezza

  2. Service of Endocrinology and Nutrition, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017, Valencia, Spain

    Víctor M. Víctor

  3. Department of Physiology, University of Valencia, INCLIVA, Valencia, Spain

    Víctor M. Víctor

  4. CIBERehd- Department of Pharmacology, University of Valencia, 46010, Valencia, Spain

    Víctor M. Víctor

Authors
  1. Teresa Vezza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Víctor M. Víctor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Víctor M. Víctor.

Ethics declarations

Funding

This research was supported by the European Regional Development Fund (ERDF ‘‘A way to build Europe’’); Generalitat Valenciana, Conselleria de Educación, Universidades y Empleo (Grant PROMETEO CIPROM/2022/32), Spanish Ministry of Science and Innovation (CIBERehd CB06/04/0071 and PI22/00424). T.V. is the recipient of a Miguel Servet contract (CP22/00153) from the Carlos III Health Institute.

Conflicts of Interest

The authors declare no potential conflicts of interest that might be relevant to this manuscript.

Author Contributions

All authors participated in the writing, reviewing, and editing of this manuscript.

Availability of Data and Materials

Not applicable.

Ethics Approval

Not applicable.

Code Availability

Not applicable.

Consent to Participate

Not applicable.

Consent to Publication

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vezza, T., Víctor, V.M. Beyond Weight Loss: Evaluating Cardiovascular Advantages of GLP-1 Receptor Agonists. Am J Cardiovasc Drugs (2024). https://doi.org/10.1007/s40256-024-00650-8

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40256-024-00650-8

Search

Navigation